Loading
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
Previous close
$7.10
−$0.04 · -0.56%
Regular session · ET · Market data may be delayed.
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
Day range
Current $7.10
52-week range
Current $7.10
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
2
Overpriced
Sentiment
63
Bullish
Risk
47
Elevated Risk
Momentum
68
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
Day range
Current $7.10
52-week range
Current $7.10
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 9.68M USD | 3.93M USD | 6.23M USD | 26.91M USD | 14.27M USD |
| Cost of goods sold | 6.1M USD | 4.27M USD | 6.12M USD | 6.34M USD | 53.68M USD |
| Gross profit | 3.59M USD | −342K USD | 106K USD | 20.57M USD | −39.41M USD |
| Research and development | 40.06M USD | 53.07M USD | 48.61M USD | 47.17M USD | 47.93M USD |
| Selling, general, and administrative | 70.13M USD | 41.29M USD | 40.42M USD | 48.01M USD | — |
| Operating expenses | 110.19M USD | 134.69M USD | 99.86M USD | 96.3M USD | 52.54M USD |
| Interest income | 3.22M USD | 1.42M USD | 3.24M USD | 133K USD | 171K USD |
| Interest expense | 3.87M USD | 6K USD | 468K USD | 6.77M USD | 18.76M USD |
| Depreciation and amortization | 3.2M USD | 4.53M USD | 6.67M USD | 10.77M USD | 13.76M USD |
| Operating income | −106.6M USD | −135.03M USD | −99.76M USD | −75.73M USD | −91.95M USD |
| Net income | −250.64M USD | −126.24M USD | −95.9M USD | 28.32M USD | −92.17M USD |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$18.00
153.52% upsideFunds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI53.95M0.47%11.49B USD0.35%$163.81-0.35%
Vanguard Morningstar Total Stock Market ETFVTI35.68M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM35.42M0.04%80.51B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF12.83M0.01%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Growth ETFIWO12.66M0.09%14.7B USD0.24%$377.54+0.12%
First Trust Small Cap Growth AlphaDEX FundFYC11.93M0.84%1.43B USD0.70%$119.54+0.04%
iShares Biotechnology ETFIBB8.56M0.08%10.73B USD0.44%$211.92-0.88%
Fundstrat Granny Shots US Small- & Mid-Cap ETFGRNJ7.98M1.61%460.75M USD0.75%$29.31+0.90%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOFirst Trust Small Cap Growth AlphaDEX FundFYCiShares Biotechnology ETFIBBFundstrat Granny Shots US Small- & Mid-Cap ETFGRNJAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
